Company: IMCR
Filing Date: 2025-03-24
Form Type: PRE 14A
Source: 0001140361-25-010035
Chunk: 45

Company: Immunocore Holdings plc
Filing Date: 2025-03-24
Form: PRE 14A
Chunk 45
---
 with Deloitte LLP the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”) and the SEC. The audit committee has also received the written disclosures and the letter from Deloitte LLP required by applicable requirements of the PCAOB regarding the independent accountants’ communications with the audit committee concerning independence and has discussed with Deloitte LLP the accounting firm’s independence. Based on the foregoing, the audit committee has recommended to our board of directors that the audited financial statements be included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and filed with the SEC. Audit Committee of the Board of Directors of Immunocore Holdings plc Siddharth Kaul (Chairman) Roy S. Herbst, M.D., Ph.D. Robert Perez Professor Sir Peter Ratcliffe Remuneration Committee Our remuneration committee is composed of Professor Sir Bell, Dr. Herbst, Mr. Kaul, Mr. Krishana and Ms. Peterson, and assists the board of directors in determining executive officer compensation. Ms. Peterson serves as chair of the remuneration committee. Mr. Coy previously served as a member of the remuneration committee until his resignation from our board of directors on January 1, 2025, the effective date of his appointment as our Chief Financial Officer. Our board of directors has determined that each of these individuals is “independent” as defined under the applicable listing standards of Nasdaq, including the standards specific to members of a remuneration committee. The remuneration committee’s responsibilities include:

| • | reviewing, modifying and overseeing the company’s overall compensation strategy and policies in light of our specific business objectives; |

| • | reviewing and approving the compensation and other terms of employment of our Chief Executive Officer; |

| • | reviewing and approving all elements of the compensation and other terms of employment of the executive officers and other senior management reporting directly to the Chief Executive Officer; |

| • | undertaking sole responsibility for the appointment, authority to select, retain, and terminate any compensation and oversight of the work of compensation consultants, legal counsel, or any other advisors engaged for the purpose of advising the remuneration committee; |

32

TABLE OF CONTENTS

| • | exercising full power and authority to adopt, amend, terminate, and administer our equity award, pension, and profit sharing plans, incentive plans, bonus plans, executive benefit plans, stock purchase plans, deferred compensation plans and other similar programs; |